New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
06:57 EDTBDSIBioDelivery Sciences risk/reward profile favorable, says William Blair
William Blair reiterates an Outperform rating on shares of BioDelivery Sciences ahead of the June 7 PDUFA date for Bunavail, the company's buprenorphine/naloxone sublingual film for the treatment of opioid addiction. The firm says the FDA has been focused on new therapies for opioid addiction given the current opioid-abuse crisis. It views the risk/reward for BioDelivery shares as favorable and has a $16 price target for the stock.
News For BDSI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for BDSI

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use